The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
This grant aims to fund projects focused on utilizing genome or epigenome editing techniques to validate and characterize genes or variants linked to substance use disorder-related phenotypes. The goal is for the genetic resources developed through these projects to be widely shared with the scientific community. This sharing is intended to facilitate further research into the neurobiological mechanisms of substance use disorders and lay the groundwork for the creation of new prevention, diagnostic, and therapeutic strategies. The grant has a two-phase funding approach: up to $125,000 per year for the R21 phase, which is limited to two years, and up to $250,000 per year for the R33 phase, which is limited to three years, with a total project period not exceeding five years.